Aardvark Therapeutics, Inc. (AARD)
| Market Cap | 156.86M -39.7% |
| Revenue (ttm) | n/a |
| Net Income | -69.89M |
| EPS | -3.20 |
| Shares Out | 21.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 177,814 |
| Open | 7.68 |
| Previous Close | 7.56 |
| Day's Range | 6.49 - 7.68 |
| 52-Week Range | 3.35 - 17.94 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 15.78 (+119.47%) |
| Earnings Date | Aug 11, 2026 |
About AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AARD stock is "Buy." The 12-month stock price target is $15.78, which is an increase of 119.47% from the latest price.
News
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps
Aardvark Therapeutics Earnings release: Q2 2026
Aardvark Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Aardvark Therapeutics Quarterly report: Q2 2026
Aardvark Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Aardvark Therapeutics Proxy statement: Proxy filing
Aardvark Therapeutics filed a proxy statement on July 10, 2026, providing details for shareholder voting and corporate governance matters.
Aardvark Therapeutics Proxy statement: Proxy filing
Aardvark Therapeutics filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it s...
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
BofA analyst Tazeen Ahmad downgraded Aardvark Therapeutics (AARD) to Underperform from Buy with a price target of $4, down from $18, following the FDA’s issuance of a clinical hold on…
Aardvark Therapeutics price target lowered to $7 from $8 at B. Riley
B. Riley analyst William Wood lowered the firm’s price target on Aardvark Therapeutics (AARD) to $7 from $8 and keeps a Buy rating on the shares. Aardvark disclosed that the…
Aardvark Therapeutics Inc trading halted, volatility trading pause
09:36 EDT Aardvark Therapeutics (AARD) Inc trading halted, volatility trading pause
Aardvark Therapeutics Inc trading resumes
09:41 EDT Aardvark Therapeutics (AARD) Inc trading resumes
Aardvark Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded Aardvark Therapeutics (AARD) to Neutral from Buy with no price target after the FDA placed a full clinical hold on ARD-101. While management noted their FDA interactions have…
Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded Aardvark Therapeutics (AARD) to Underweight from Equal Weight with a price target of $3, down from $7. The company announced last night that the FDA placed ARD-101…
Aardvark Therapeutics announces FDA clinical hold on ARD-101
Aardvark Therapeutics (AARD) announced that the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101, related to the company’s prev...
FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome
Aardvark Therapeutics on Thursday said the U.S. Food and Drug Administration placed a full clinical hold on its drug to treat extreme hunger linked to the rare disorder Prader-Willi syndrome, haltin...
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule...
Aardvark Therapeutics price target lowered to $18 from $20 at BofA
BofA lowered the firm’s price target on Aardvark Therapeutics (AARD) to $18 from $20 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)
“We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best…
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operat...
Aardvark Therapeutics Quarterly report: Q1 2026
Aardvark Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Aardvark Therapeutics Earnings release: Q1 2026
Aardvark Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
B. Riley analyst William Wood lowered the firm’s price target on Aardvark Therapeutics (AARD) to $8 from $32 and keeps a Buy rating on the shares. Aardvark paused multiple ARD-101…
Aardvark Therapeutics files $400M mixed securities shelf
17:11 EDT Aardvark Therapeutics (AARD) files $400M mixed securities shelf
Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)
As of December 31, 2025, Aardvark had cash, cash equivalents and short-term investments of $110M, compared to $73.7M as of December 31, 2024. Based on current operating plans, Aardvark believes…
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026
Aardvark Therapeutics Annual report: Q4 2025
Aardvark Therapeutics has published its Q4 2025 annual report on March 23, 2026.